R&D | January 23, 2026
Bayer and Vanderbilt launch five-year partnership to accelerate innovative therapies
The partnership initially will focus on cardiovascular and kidney diseases
The partnership initially will focus on cardiovascular and kidney diseases
This certification paves the way for CORONA's entry into five EAEU member nations- Russia, Kyrgyzstan, Armenia, Belarus, and Kazakhstan-under a B2B business model
This marks the second indication for which gumokimab has gained NDA review acceptance
The registrations grant Neurizon exclusive rights to use and defend its brand across its core operating regions
Berendsen brings over 15 years of financial leadership experience spanning professional services and international trade
The injectable borofalan (10B), developed by CNNC Headway—a subsidiary of China Isotope & Radiation Corporation (CIRC) under the China National Nuclear Corporation (CNNC)—has officially entered Phase I clinical trials
ALTO-207 combines pramipexole, a dopamine D3-preferring D3/D2 agonist approved for Parkinson’s disease
The new investment will fuel expansion of Avalon's Diagnostic Intelligence capabilities
Myqorzo, a selective small-molecule cardiac myosin inhibitor, is designed to improve functional capacity and relieve symptoms in oHCM
The expanded agreement significantly widens the scope of integrated services across the entire drug development lifecycle
Subscribe To Our Newsletter & Stay Updated
